Kronos Bio Inc (KRON) volume exceeds 0.53 million: A new investment opportunity for investors

On Monday, Kronos Bio Inc (NASDAQ: KRON) opened higher 4.72% from the last session, before settling in for the closing price of $1.06. Price fluctuations for KRON have ranged from $0.73 to $2.29 over the past 52 weeks.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Company’s average yearly earnings per share was noted 14.14% at the time writing. With a float of $37.74 million, this company’s outstanding shares have now reached $56.97 million.

Kronos Bio Inc (KRON) Insider Updates

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Kronos Bio Inc is 35.28%, while institutional ownership is 35.10%. The most recent insider transaction that took place on Jan 04, was worth 14,214. In this transaction Chief Medical Officer & VP of this company sold 12,009 shares at a rate of $1.18, taking the stock ownership to the 315,246 shares. Before that another transaction happened on Jan 04, when Company’s COO & General Counsel sold 10,676 for $1.18, making the entire transaction worth $12,636. This insider now owns 928,966 shares in total.

Kronos Bio Inc (KRON) Performance Highlights and Predictions

If we go through the results of last quarter, which was made public on 9/29/2023, the company posted -$0.54 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -$0.51) by -$0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.48 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 14.14% per share during the next fiscal year.

Kronos Bio Inc (NASDAQ: KRON) Trading Performance Indicators

Check out the current performance indicators for Kronos Bio Inc (KRON). In the past quarter, the stock posted a quick ratio of 7.46. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.18.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.08, a number that is poised to hit -0.53 in the next quarter and is forecasted to reach -1.91 in one year’s time.

Technical Analysis of Kronos Bio Inc (KRON)

The latest stats from [Kronos Bio Inc, KRON] show that its last 5-days average volume of 0.19 million was superior to 0.11 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 25.08%. Additionally, its Average True Range was 0.10.

During the past 100 days, Kronos Bio Inc’s (KRON) raw stochastic average was set at 48.95%, which indicates a significant increase from 28.24% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.31% in the past 14 days, which was lower than the 86.14% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $1.1930, while its 200-day Moving Average is $1.4011. Now, the first resistance to watch is $1.1767. This is followed by the second major resistance level at $1.2433. The third major resistance level sits at $1.3067. If the price goes on to break the first support level at $1.0467, it is likely to go to the next support level at $0.9833. Assuming the price breaks the second support level, the third support level stands at $0.9167.

Kronos Bio Inc (NASDAQ: KRON) Key Stats

There are currently 58,317K shares outstanding in the company with a market cap of 64.74 million. Presently, the company’s annual sales total 0 K according to its annual income of -133,200 K. Last quarter, the company’s sales amounted to 920 K and its income totaled -31,370 K.